Immunome, Inc. (NASDAQ:IMNM) Receives $28.83 Consensus Price Target from Analysts

Immunome, Inc. (NASDAQ:IMNM) has received an average rating of “Buy” from the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have covered the stock in the last year is $28.83.

Several research analysts have recently issued reports on the company. Wedbush reaffirmed an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a research note on Friday, October 25th. Piper Sandler dropped their price target on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Finally, Stephens started coverage on shares of Immunome in a research note on Friday, November 8th. They issued an “overweight” rating and a $30.00 price objective on the stock.

Immunome Stock Up 16.8 %

NASDAQ IMNM opened at $13.47 on Tuesday. Immunome has a twelve month low of $6.93 and a twelve month high of $30.96. The business’s fifty day moving average is $12.37 and its 200 day moving average is $13.52. The company has a market cap of $840.76 million, a price-to-earnings ratio of -1.66 and a beta of 1.82.

Insiders Place Their Bets

In related news, insider Robert Lechleider purchased 15,805 shares of the firm’s stock in a transaction on Thursday, November 21st. The stock was purchased at an average cost of $9.48 per share, with a total value of $149,831.40. Following the completion of the purchase, the insider now owns 15,805 shares in the company, valued at approximately $149,831.40. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Clay B. Siegall bought 66,057 shares of the firm’s stock in a transaction that occurred on Thursday, November 21st. The stock was purchased at an average cost of $9.54 per share, with a total value of $630,183.78. Following the completion of the transaction, the chief executive officer now directly owns 485,693 shares in the company, valued at $4,633,511.22. This represents a 15.74 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 102,862 shares of company stock worth $978,045. Company insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On Immunome

A number of hedge funds have recently added to or reduced their stakes in the company. Arizona State Retirement System raised its position in shares of Immunome by 9.2% during the second quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock worth $131,000 after purchasing an additional 918 shares during the period. Clear Creek Financial Management LLC increased its stake in Immunome by 18.2% during the 2nd quarter. Clear Creek Financial Management LLC now owns 26,188 shares of the company’s stock valued at $317,000 after purchasing an additional 4,035 shares in the last quarter. AQR Capital Management LLC raised its holdings in Immunome by 34.6% during the second quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock worth $194,000 after buying an additional 4,129 shares during the last quarter. Cerity Partners LLC lifted its stake in shares of Immunome by 10.5% in the third quarter. Cerity Partners LLC now owns 53,103 shares of the company’s stock valued at $776,000 after buying an additional 5,043 shares in the last quarter. Finally, Quest Partners LLC acquired a new position in shares of Immunome during the second quarter valued at about $81,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.